Therapix Biosciences Ltd. (NASDAQ:TRPX) is a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments. Despite positive news released this morning regarding the biotech company's antibacterial THC-based treatment called THX-150, shares of the Israeli-based company are down almost 5% in intra-day trading.
Professor Itamar Shalit, M.D., Associate Professor in Pediatrics at Tel Aviv University and a leading authority on infectious diseases, said, "In our earlier non-clinical collaboration with Therapix, THX-150 was effective in eradicating resistant bacterial strains significantly better to what was observed in the bacterial controls treated only with antibiotics."
Now, the company will be initiating non-clinical studies to evaluate the efficacy of its proprietary compound THX-150 in collaboration with the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center.
Everything You Need to Know About THX-150
THX-150 is Therapix Biosciences' dronabinol-based drug candidate intended for the treatment of infectious diseases. Dronabinol is the synthetic version of tetrahydrocannabinol, a.k.a. THC, which is the psychoactive cannabinoid contained naturally in the cannabis plant. Cannabinoids such as THC have been shown for some time to posses antibacterial properties, which give us reason to believe that the recently announced non-clinical studies should yield positive results.
According to the World Health Organization, antimicrobial resistance, classified as a 'serious threat', occurs when microorganisms are exposed to antimicrobial drugs. As a result, medicines become ineffective and infections persist, increasing the risk of spread. New resistance mechanisms are emerging globally, threatening the ability to treat common infectious diseases. Without effective antimicrobials for prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery are jeopardized. Antimicrobial resistance increases the cost of healthcare with lengthier stays in hospitals and more intensive care required.
"In our preliminary studies, we observed that cannabinoids increase the potency and decrease the minimal required therapeutic dosages of antibacterial agents, thus potentially minimizing the development of drug resistance and reducing side effects from antibiotic treatment," commented Adi Zuloff-Shani, Ph.D., Chief Technology Officer of Therapix.
Other Dronabinol Drug Companies
While Therapix is the only company we track seeking to use dronabinol for antibacterial purposes, there are a handful of other companies using the lab-made synthetic version of THC for other indications.
For instance, AbbVie (NYSE:ABBV) has had a dronabinol-based capsule called Marinol approved for various indications since the 1980's including loss of appetite associated with weight loss in patients with AIDS, and also to fight nausea and vomiting associated with cancer chemotherapy.
Another company, Insys Therapeutics (NASDAQ:INSY), has the only FDA-approved liquid form of Dronabinol which the company markets under the name SYNDROS for the same indications as AbbVie's Marinol.
In efforts to provide patients with even more choice as to how they consume their dronabinol, Axim Biotechnologies (OTC:AXIM) is developing a dronabinol-based controlled-release chewing gum product utilizing the company's existing intellectual property.
As for companies like Therapix seeking to break away from dronabinol's traditional uses, there's RespireRX Pharmaceuticals (OTC:RSPI), which is trying to get FDA approval for its dronabinol-based treatment for obstructive sleep apnea.
We'll be sure to keep readers informed as more developments are released regarding Therapix Biosciences' non-clinical studies. Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.